Supplementary Table S3 from Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial
María Vidal(Inserm), Meritxell Bellet(Vall d'Hebron Hospital Universitari), Claudette Falato(Karolinska Institutet), Xavier González(Breast Cancer Research Foundation), Milana A. Bergamino(Breast Cancer Research Foundation), Isaac Cebrecos(Hospital Clínic de Barcelona), Miguel A. Luna, J.M. Ferrero-Cafiero(Solti), Alejandra Espinosa Guerrero(Solti), Tomás Pascual(Breast Cancer Research Foundation), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Mireia Margelí Vila(Institut Català d'Oncologia), Patricia Galván(Vall d'Hebron Institute of Oncology), Esther Sanfeliu(Hospital Clínic de Barcelona), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Fernando Salvador(Institute for Research in Biomedicine), Kepa Amillano(Hospital Universitari Sant Joan de Reus), Montserrat Muñoz-Mateu(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Aleix Prat(Hospital Clínic de Barcelona), Tomás Cortadellas(Universitat Autònoma de Barcelona), Christian Sisó(Vall d'Hebron Hospital Universitari)
Cited by 0
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
|Annals of Oncology|2021|799
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684